Oxford BioDynamics' CRC Diagnostic Test Could Reduce Unnecessary Patient Follow-Ups

Oxford BioDynamics has reported promising clinical study data for its new blood-based colorectal no-stool test, EpiSwitch NST. If introduced in the clinic, the test could reduce false positive test results, the company said.

In the multi-institutional study published in the peer-reviewed journal, Cancers, EpiSwitch NST performed at a similar level to major market players, Exact Science’s Cologuard, Freenome’s PREEMPT, and Guardant’s Shield in...